These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2979281)

  • 1. Cost of treating arthritis and NSAID-related gastrointestinal side-effects.
    Bloom BS
    Aliment Pharmacol Ther; 1988; 2 Suppl 1():131-8. PubMed ID: 2979281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.
    Bloom BS
    Am J Med; 1988 Feb; 84(2A):20-4. PubMed ID: 3348239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care resource utilization and costs of NSAID-induced gastrointestinal toxicity. A population-based study in Switzerland.
    Delcò F; Michetti P; Beglinger C; Fried M; Szucs TD
    Digestion; 2004; 69(1):10-9. PubMed ID: 14755148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hidden costs of arthritis treatment and the cost of new therapy--the burden of non-steroidal anti-inflammatory drug gastropathy.
    Moore RA
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():7-15; discussion 35-42. PubMed ID: 12173280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The iatrogenic costs of NSAID therapy: a population study.
    Sturkenboom MC; Romano F; Simon G; Correa-Leite ML; Villa M; Nicolosi A; Borgnolo G; Bianchi-Porro G; Mannino S
    Arthritis Rheum; 2002 Apr; 47(2):132-40. PubMed ID: 11954006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs.
    Smalley WE; Griffin MR; Fought RL; Ray WA
    J Gen Intern Med; 1996 Aug; 11(8):461-9. PubMed ID: 8872783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final report on the cost of treating arthritic disease: comparison between salicylates and nonsalicylate nonsteroidal anti-inflammatory drugs.
    Kolodny AL; Klipper A
    Semin Arthritis Rheum; 1985 Feb; 14(3 Suppl 1):20-4. PubMed ID: 3938874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects].
    Lanas A
    Med Clin (Barc); 2000; 114 Suppl 3():46-53. PubMed ID: 10994564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM; Chiou CF; Ofman JJ
    Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.
    Chevat C; Peña BM; Al MJ; Rutten FF
    Pharmacoeconomics; 2001; 19 Suppl 1():17-32. PubMed ID: 11280103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs.
    Laine L; Wogen J; Yu H
    Gastroenterology; 2003 Aug; 125(2):389-95. PubMed ID: 12891540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.
    Singh G; Rosen Ramey D
    J Rheumatol Suppl; 1998 May; 51():8-16. PubMed ID: 9596549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic consequences of NSAID-induced gastrointestinal damage.
    de Pouvourville G; Tasch RF
    Eur J Rheumatol Inflamm; 1993; 13(1):33-40. PubMed ID: 7821337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal events related to the use of non-steroidal anti-inflammatory drugs: some clinical and economic aspects.
    Eliakim R; Rachmilewitz D
    Isr J Med Sci; 1997 Oct; 33(10):696-9. PubMed ID: 9397147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.